| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4560939
Max Phase: Preclinical
Molecular Formula: C19H21FO3
Molecular Weight: 316.37
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: C=CC[C@H]1C[C@]2(C(C)Cc3ccc(F)cc3)OCOC2=CC1=O
Standard InChI: InChI=1S/C19H21FO3/c1-3-4-15-11-19(18(10-17(15)21)22-12-23-19)13(2)9-14-5-7-16(20)8-6-14/h3,5-8,10,13,15H,1,4,9,11-12H2,2H3/t13?,15-,19+/m0/s1
Standard InChI Key: YBMNAYUTESYBFE-GSTZGWFYSA-N
Associated Targets(Human)
M14 47487 Activities
NCI-H460 60772 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 316.37 | Molecular Weight (Monoisotopic): 316.1475 | AlogP: 3.80 | #Rotatable Bonds: 5 |
| Polar Surface Area: 35.53 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 0 |
| #RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.30 | CX LogD: 4.30 |
| Aromatic Rings: 1 | Heavy Atoms: 23 | QED Weighted: 0.78 | Np Likeness Score: 1.08 |
References
| 1. Huang Z, Williams RB, Martin SM, Lawrence JA, Norman VL, O'Neil-Johnson M, Harding J, Mangette JE, Liu S, Guzzo PR, Starks CM, Eldridge GR.. (2018) Bifidenone: Structure-Activity Relationship and Advanced Preclinical Candidate., 61 (15): [PMID:29995409] [10.1021/acs.jmedchem.7b01644] |
Source
Source(1):